‹ Screener

ProMIS Neurosciences Inc.

PMN · Pharmaceutical Preparations · 9.0M shares · -43%/yr ↓ buyback · EDGAR filings ↗

Reference price $11.33 · est. market cap ~$102M — last insider purchase, 2026-04-22 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)

Grade

F32

Dormant/near-insolvent micro-cap — near-insolvent liquidity and deep losses.

Strengths

Risks

Notable findings

Key metrics

Return on equity
3155.8%
Return on assets
-432.6%
Current ratio
0.9×
Tangible book value
-$1M
Cash & investments
$6M

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-04-22Kirwin Patrick D.Buy4.0K$11.33
2026-03-05Williams EugeneBuy2.0K$24.40
2026-03-04Williams EugeneBuy2.0K$24.00
2026-03-03Williams EugeneBuy1.0K$21.89
2026-03-02Williams EugeneBuy1.0K$22.53
2026-02-19Kaplan JohanneBuy1.6K$15.35
2026-02-03ABG Management Ltd.Buy701K$12.13
2026-02-03Cashman NeilGrant4.1K$12.13
2026-02-03Kaplan JohanneGrant2.1K$12.13
2026-02-03Warma Neil KGrant6.2K$12.13
2026-02-03Milbury Max A.Grant6.6K$12.13
2026-02-03Kirwin Patrick D.Grant3.0K$12.13
2025-10-03Milbury Max A.Buy30K$0.49
2025-07-25Jeremy M. Sclar 2012 Irrevocable Family TrustOption exercise698K
2025-07-25Jeremy M. Sclar 2012 Irrevocable Family TrustOption exercise698K
2025-07-25Jeremy M. Sclar 2012 Irrevocable Family TrustOption exercise698K
2025-07-25Sclar Jeremy M.Option exercise698K
2025-07-25Sclar Jeremy M.Option exercise698K
2025-07-25Sclar Jeremy M.Option exercise698K
2025-07-25Title 19 PromisOption exercise120K
2025-07-25Title 19 PromisOption exercise120K
2025-07-25Title 19 PromisOption exercise120K
2025-07-25GORDON MICHAEL SOption exercise120K
2025-07-25GORDON MICHAEL SOption exercise120K
2025-07-25GORDON MICHAEL SOption exercise120K
2025-06-30GORDON MICHAEL SSell93K
2025-03-13GORDON MICHAEL SOther48K
2025-02-10Cashman NeilBuy15K$0.97

All non-derivative Form 4 activity (SEC), newest first.

Clinical trials

TrialTitlePhaseStatusPrimary completion
NCT06750432 ↗PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
Alzheimer Disease, Early Onset
PHASE1Active Not Recruiting2026-12-01
NCT06105528 ↗A Phase 1a Study of PMN310 In Healthy Volunteers
Healthy Participants
PHASE1Completed2024-07-31

Source: ClinicalTrials.gov (U.S. NIH) · active studies first.

Notable events (8-K)

DateItems
2026-05-20Exec/director changeShareholder voteExhibitsfiling ↗
2026-05-12ResultsExhibitsfiling ↗
2026-03-25ResultsExhibitsfiling ↗
2026-01-30Material agreement3.02OtherExhibitsfiling ↗
2025-12-16Otherfiling ↗
2025-11-245.03OtherExhibitsfiling ↗
2025-11-19Shareholder votefiling ↗
2025-11-12ResultsExhibitsfiling ↗

Recent filings

FormFiledPeriodAccession
8-K2026-05-202026-05-200001104659-26-064545 ↗
10-Q2026-05-122026-03-310001104659-26-059035 ↗
8-K2026-05-122026-05-120001104659-26-058967 ↗
10-K2026-03-252025-12-310001104659-26-034554 ↗
8-K2026-03-252026-03-250001104659-26-034162 ↗
8-K2026-01-302026-01-290001104659-26-008325 ↗
8-K2025-12-162025-12-120001104659-25-121627 ↗
8-K2025-11-242025-11-240001104659-25-115182 ↗
8-K2025-11-192025-11-170001104659-25-113978 ↗
10-Q2025-11-122025-09-300001104659-25-109719 ↗
8-K2025-11-122025-11-120001104659-25-109714 ↗
8-K2025-10-242025-10-220001104659-25-102137 ↗